|
BG505 SOSIP Vaccine Elicited Neutralizing Monoclonal Antibodies for HIV
Application
ELISA
Western Blot
Immunohistochemistry
Specficity
HIV-1 BG505 Env protein (clone name: YRK01, YRK02).
Subtype
Monoclonal antibody.
Immunogen
HIV-1 BG505 SOSIP Env trimer.
Technical Summary
HIV-1 envelope glycoprotein (Env) is a membrane protein complex involved in receptor recognition and viral fusion with CD4+ T cells...
Published: 5/17/2022
Contributor(s): Cynthia Derdeyn, Tysheena Charles
|
|
Extended Efficacy SARS-COV-2 Vaccine
Application
A vaccine for SARS-COV-2 that can be used to protect against infection by future forms of Variant-of-Concern (VOC) or other SARS-like coronaviruses.
Key Benefits
An approach to developing a vaccine that would be effective against future mutations of SARS-COV-2.
A vaccine that elicits an immune response to conserved portions...
Published: 5/13/2022
Contributor(s): Chinglai Yang, Ling Ye, Samuel Stampfer, Rui Jin
|
|
HIV-1 Clade C Protein Immunogen as HIV-1 Vaccine
Application
Novel stabilized HIV-1 Clade C gp140 trimeric immunogen useful as a vaccine.
Key Benefits
Vaccine for HIV-1 infections.
Induces both neutralizing and V1V2 scaffold directed antibody responses.
V1V2 scaffold directed antibodies bind to multiple strains of HIV-1 from different clades including Clades B and C.
Market Summary
HIV-1...
Published: 11/20/2020
Contributor(s): Rama Amara, Sailaja Gangadhara, Tiffany Styles, Anusmita Sahoo
|
|
Live Attenuated Zika Virus Vaccines
Application
Yellow fever virus-based live attenuated Zika virus (ZIKV) vaccines.
Key Benefits
Reduces neurotropism from Zika virus.
High safety and immunogenicity of chimeric vaccines.
Market Summary
Zika virus (ZIKV) belongs to the flavivirus family of viruses, which include West Nile (WN), Japanese encephalitis (JE), yellow fever (YF), dengue...
Published: 11/2/2020
Contributor(s): Baek Kim
|
|
Boosting Immunogenicity of Vaccines Using Saponins and Agonists of the Intracellular STING Pathway
Application
Vaccine formulation of an activator of the stimulator of interferon genes (STING) pathway and saponin adjuvant for enhanced protection of aged population.
Key Benefits
Significantly improved protective immunity of vaccine in the aged.
More efficient than the current methods of influenza vaccination of population 65 years of age or...
Published: 4/24/2020
Contributor(s): Elena Vassilieva, Richard Compans
|
|
Virus-Like Particles as RSV Vaccine Candidate
Application
Virus-like particle (VLP) vaccine candidate(s) to prevent respiratory syncytial virus (RSV) infection.
Key Benefits
Candidates may have the most effective anti-viral and anti-inflammatory response.
Potentially protects elderly and immunocompromised patients from re-infection with the RSV virus.
Efficient, tunable and stable production...
Published: 1/15/2020
Contributor(s): Binh Ha, Larry Anderson, Elizabeth Wright
|
|
Trimeric Immunogen for HIV-1 Vaccination
Application
Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine.
Key Benefits
Possible oral administration.
Broadly cross-reactive against HIV-1 panel.
Promotes antibody responses as both a primary immunogen and boosting immunogen.
Market Summary
Antiretroviral therapy (ART) has dramatically prolonged...
Published: 8/26/2019
Contributor(s): Rama Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
|
|
Glycoprotein Tetramer for Identifying Antigen-specific B Cells
ApplicationEctodomain of viral glycoprotein tetramers detects antigen-specific memory B Cells.Key BenefitsViral glycoprotein tetramers detect antigen-specific memory B cells in the peripheral blood and tissues.Hepatitis C virus E2 protein triggers immune response, which may yield an effective vaccine against hepatitis C virus.Market SummaryHepatitis...
Published: 5/9/2019
Contributor(s): Arash Grakoui, Joseph Marcotrigiano
|
|
ReadyVax
ApplicationStandalone smartphone app to increase vaccinations and improve vaccine knowledge for providers, pharmacists, and the general public.Key BenefitsProvides detailed information about a variety of vaccines and diseases. Sends out alerts and updates. Market SummaryVaccines prevent millions of cases of infectious diseases each year; however, many...
Published: 4/2/2019
Contributor(s): Saad Omer, Robert Bednarczyk, Paula Frew, Walter Orenstein, Ines Gonzalez-Casanova, Neal Halsey, Daniel Salmon
|
|
Human Monoclonal Antibodies Against Ebola Virus
ApplicationAntibodies that bind and neutralize Ebola virus glycoprotein (GP) for use in vaccination or treatment of Ebola virus disease.Key BenefitsHigher binding affinity for Ebola virus GP than closest competitor.Can be used prophylactically or for treatment of Ebola virus disease.Market SummaryThe Ebola virus is an RNA virus with a membrane composed...
Published: 3/26/2019
Contributor(s): Rafi Ahmed
|
Emory UniversityOffice of Technology Transfer